Lupin launches generic drug to treat HIV 1 infection

It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

50
Medicine Tablets
Picture: Pixabay

Last Updated on July 1, 2021 by The Health Master

Global pharma major Lupin Limited announced the launch of emtricitabine and tenofovir disoproxil fumarate tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (USFDA).

Emtricitabine and tenofovir disoproxil fumarate tablets 200 mg/300 mg, are the generic equivalent of Truvada tablets 200 mg/300 mg, of Gilead Sciences, Inc., and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and tenofovir disoproxil fumarate tablets had estimated annual sales of US$ 2.1 billion in the US, according to IQVIA MAT March 2021.

Dr Reddy’s Lab commercially launches 2DG

Dr. Reddy’s Labs launches Icosapent Ethyl Capsules

Cadila Pharma launches Posaconazole to treat fungal diseases

Cipla launches Vitamin C Chewable Tablets with Gold Supplement

Glenmark launches drug to treat Pulmonary disease in UK

Alkem launches Drug for Epilepsy treatment in India

Latest Notifications: DMROA (Drugs and Magic Remedies Act)

Copyright – An article (Part-1)

Copyright – An article (Part-2)

Pharma Industry: On Ban on Methylcobalamin Pan India

40 Pharma Firms showed interest in anti Covid drug: DRDO

15,000 StayHappi Pharmacy Stores to be opened

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner